Company News

Uni-Bio Science Announces 2023 Annual Results

Marketing application of Diquafosol Sodium eye drops has been officially accepted by the China National Medical Products Administration (NMPA)

As A Breakthrough Drug For The Expansive Osteoporosis Market, Bogutai® (Teriparatide Injection) Has Been Officially Approved By The China National Medical Products Administration (NMPA)

Uni-Bio Science 2023 Interim Results，Achieved Record High Profit of HK$39.4M

Uni-Bio Science Announces 2022 Annual Results，Record High Turnover of HK$440.3 Million and HK$38.5 Million Profit Achieved Expanding Portfolio with New Drug Innovations and Strategic R&D Partnerships

The four-pillar cultivates new growth engines for high-quality development | Uni-Bio Science Group's 2023 Annual Strategy Conference was successfully held The four-pillar cultivates new growth engines for high-quality development | Uni-Bio Science Group's 2023 Annual Strategy Conference was successfully held

Join hands together and Build up a head of steam | Uni-Bio Science Group's 2023 Annual Marketing Conference was successfully held

Uni-Bio Science's Chairman Won HK Innopreneur Awards – GBA+ Award

2022 Interim Results Pinup® and Boshutai® Generated Remarkable Turnover while Achieving Record High Profit Aim to Build a Highly Commercial-Driven and Specialized R&D Platform